These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
344 related articles for article (PubMed ID: 37108495)
1. Identification and Clinical Significance of Pancreatic Cancer Stem Cells and Their Chemotherapeutic Drug Resistance. Kuo YC; Kou HW; Hsu CP; Lo CH; Hwang TL Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108495 [TBL] [Abstract][Full Text] [Related]
2. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Shah AN; Summy JM; Zhang J; Park SI; Parikh NU; Gallick GE Ann Surg Oncol; 2007 Dec; 14(12):3629-37. PubMed ID: 17909916 [TBL] [Abstract][Full Text] [Related]
3. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Hong SP; Wen J; Bang S; Park S; Song SY Int J Cancer; 2009 Nov; 125(10):2323-31. PubMed ID: 19598259 [TBL] [Abstract][Full Text] [Related]
4. Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition. Quint K; Tonigold M; Di Fazio P; Montalbano R; Lingelbach S; Rückert F; Alinger B; Ocker M; Neureiter D Int J Oncol; 2012 Dec; 41(6):2093-102. PubMed ID: 23026911 [TBL] [Abstract][Full Text] [Related]
5. Cancer stem-like cells enriched in Panc-1 spheres possess increased migration ability and resistance to gemcitabine. Yin T; Wei H; Gou S; Shi P; Yang Z; Zhao G; Wang C Int J Mol Sci; 2011; 12(3):1595-604. PubMed ID: 21673909 [TBL] [Abstract][Full Text] [Related]
6. Pancreatic cancer cells resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells. Du Z; Qin R; Wei C; Wang M; Shi C; Tian R; Peng C Dig Dis Sci; 2011 Mar; 56(3):741-50. PubMed ID: 20683663 [TBL] [Abstract][Full Text] [Related]
7. Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines. Yao J; An Y; Wie JS; Ji ZL; Lu ZP; Wu JL; Jiang KR; Chen P; Xu ZK; Miao Y Swiss Med Wkly; 2011; 141():w13208. PubMed ID: 21630164 [TBL] [Abstract][Full Text] [Related]
8. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo. Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920 [TBL] [Abstract][Full Text] [Related]
9. Gemcitabine treatment induces endoplasmic reticular (ER) stress and subsequently upregulates urokinase plasminogen activator (uPA) to block mitochondrial-dependent apoptosis in Panc-1 cancer stem-like cells (CSCs). Wang L; Zhang Y; Wang W; Zhu Y; Chen Y; Tian B PLoS One; 2017; 12(8):e0184110. PubMed ID: 28854261 [TBL] [Abstract][Full Text] [Related]
11. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210. Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003 [TBL] [Abstract][Full Text] [Related]
12. Fzd7/Wnt7b signaling contributes to stemness and chemoresistance in pancreatic cancer. Zhang Z; Xu Y; Zhao C Cancer Med; 2021 May; 10(10):3332-3345. PubMed ID: 33934523 [TBL] [Abstract][Full Text] [Related]
13. The Metastatic Potential and Chemoresistance of Human Pancreatic Cancer Stem Cells. Bhagwandin VJ; Bishop JM; Wright WE; Shay JW PLoS One; 2016; 11(2):e0148807. PubMed ID: 26859746 [TBL] [Abstract][Full Text] [Related]
14. Gemcitabine-induced epithelial-mesenchymal transition-like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal-like phenotype. El Amrani M; Corfiotti F; Corvaisier M; Vasseur R; Fulbert M; Skrzypczyk C; Deshorgues AC; Gnemmi V; Tulasne D; Lahdaoui F; Vincent A; Pruvot FR; Van Seuningen I; Huet G; Truant S Mol Carcinog; 2019 Nov; 58(11):1985-1997. PubMed ID: 31373074 [TBL] [Abstract][Full Text] [Related]
15. The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells. Cioffi M; Trabulo SM; Sanchez-Ripoll Y; Miranda-Lorenzo I; Lonardo E; Dorado J; Reis Vieira C; Ramirez JC; Hidalgo M; Aicher A; Hahn S; Sainz B; Heeschen C Gut; 2015 Dec; 64(12):1936-48. PubMed ID: 25887381 [TBL] [Abstract][Full Text] [Related]
16. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205. Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008 [TBL] [Abstract][Full Text] [Related]
17. MiR-200a inhibits epithelial-mesenchymal transition of pancreatic cancer stem cell. Lu Y; Lu J; Li X; Zhu H; Fan X; Zhu S; Wang Y; Guo Q; Wang L; Huang Y; Zhu M; Wang Z BMC Cancer; 2014 Feb; 14():85. PubMed ID: 24521357 [TBL] [Abstract][Full Text] [Related]
18. Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer. Avan A; Quint K; Nicolini F; Funel N; Frampton AE; Maftouh M; Pelliccioni S; Schuurhuis GJ; Peters GJ; Giovannetti E Curr Pharm Des; 2013; 19(5):940-50. PubMed ID: 22973962 [TBL] [Abstract][Full Text] [Related]
19. JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells. Suzuki S; Okada M; Shibuya K; Seino M; Sato A; Takeda H; Seino S; Yoshioka T; Kitanaka C Oncotarget; 2015 Jan; 6(1):458-70. PubMed ID: 25473894 [TBL] [Abstract][Full Text] [Related]
20. Up-regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine-resistant pancreatic cancer cells. Zhao H; Duan Q; Zhang Z; Li H; Wu H; Shen Q; Wang C; Yin T J Cell Mol Med; 2017 Sep; 21(9):2055-2067. PubMed ID: 28244691 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]